MASTER Trial: Prospective, multicentre, randomized trial evaluating the MGuard stent in the treatment of patients with acute myocardial infarction with ST segment elevation (STEMI).

Foreword: The EPS MGUARD stent (embolic protection stent) has a fine metal structure covered by a thin polyethylene fiber mesh with pores of 5 microns wrapping the stent that might prevent distal embolization during primary angioplasty and would therefore be particularly attractive during primary angioplasty.

Methods and Results: We included 432 patients referred for primary angioplasty having 70% ST). In two thirds of the population we used a predilatation thromboaspiration catheter and predilatation reached 50%. The MGuard direct implantation was 12% and 10.6% in the conventional group (p = NS). The MGuard group had a higher rate of final TIMI III (91.7% versus 82.9%, p = 0.006) and ST resolution (57.8% versus 44.7%, p = 0.008). The MGuard group showed a tendency to have lower cardiac mortality at 30 days (0 versus 1.9%, p = 0.06), with no observed difference in the rate of reinfarction, thrombosis or emergency reintervention.

Conclusion: The MGuard stent in a primary angioplasty context is associated with a better rate of ST resolution and final TIMI III flow. Studies with a larger sample size are needed to confirm the preliminary results observed in this randomized study.

Read article

6_gregg_stone_slides
Gregg Stone.
2012-10-24

Original title: The MASTER Trial a prospective, randomized, multicenter evaluation of a PET Micronet Mesh Covered Stent (MGuard) in STEMI.

More articles by this author

PARTNER cohort B: Clinical events at 3 years follow-up in patients with

Background: Percutaneous aortic valve implantation (TAVI) is the treatment of choice for patients with severe aortic stenosis considered inoperable according to clinical outcomes at...

ETAP: Endovascular treatment of atherosclerotic popliteal artery lesions: a prospective, multi-center, randomized study.

Introduction: The popliteal artery is a vessel considered unfavorable for the implantation of a stent due to the forces exerted in the popliteal fossa...

ISAR-LEFT MAIN 2: Everolimus-eluting stents versus Zotarolimus eluting stents in the treatment of the unprotected left coronary trunk.

Summary: Second-generation drug-eluting stents have shown better results than their predecessors. In this study we compare two second-generation drug stents in patients with unprotected...

FAME 2: Cost-effectiveness of FFR-guided angioplasty in patients with stable angina

Introduction: FAME study 2, presented at the European Congress of Cardiology 2012, is a multicenter study that randomized patients with stable angina FFR-guided angioplasty...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long-Term Predictors of Valve Deterioration After TAVI

Transcatheter aortic valve implantation (TAVI) has become an innovative technology for the treatment of patients with severe aortic valve stenosis. Initially implemented in elderly...

Coronary access after TAVI with fourth- and fifth-generation Evolut valves: the EPROMPT-CA study

The expansion of transcatheter aortic valve implantation (TAVI) toward younger and lower-risk patients has increased the relevance of post-procedural coronary access. In this context,...

Morpheus Global Registry: Safety and efficacy of the long tapered BioMime™ Morph stent in complex coronary lesions

Percutaneous coronary intervention in long coronary lesions continues to represent a technical and clinical challenge, in which the use of conventional cylindrical stents may...